. 2019 May 28;9:439. doi: 10.3389/fonc.2019.00439

Table 2.

Univariate analysis of 82 RCC patients on all biomarkers and overall survival.

Parameters	OS
	Hazard ratio	95%CI	P
PD-L $1_{IM}^{+}$	1.001	0.999–1.002	0.454
PD-L $1_{CT}^{+}$	1.001	1.000–1.001	0.115^*
CD $3_{IM}^{+}$	0.998	0.995–1.001	0.193^*
CD $3_{CT}^{+}$	0.992	0.986–0.998	0.013^**
CD $4_{IM}^{+}$	0.996	0.992–1.001	0.127^*
CD $4_{CT}^{+}$	0.995	0.988–1.002	0.149^*
CD45RO $_{IM}^{+}$	0.997	0.992–1.001	0.134^*
CD45RO $_{CT}^{+}$	0.999	0.993–1.004	0.677
Foxp $3_{IM}^{+}$	1.000	0.999–1.002	0.684
Foxp $3_{CT}^{+}$	1.000	0.998–1.002	0.776
CD4⁺Foxp $3_{IM}^{+}$	1.002	0.994–1.009	0.648
CD4⁺Foxp $3_{CT}^{+}$	1.004	0.991–1.018	0.528
CD4⁺Foxp3⁺CD45RO $_{IM}^{+}$	0.993	0.970–1.017	0.591
CD4⁺Foxp3⁺CD45RO $_{CT}^{+}$	1.018	0.992–1.044	0.182^*
TNFR $2_{IM}^{+}$	1.000	0.998–1.003	0.679
TNFR $2_{CT}^{+}$	1.001	1.000–1.002	0.104^*
CD4⁺Foxp3⁺TNFR $2_{IM}^{+}$	1.004	0.995–1.013	0.365
CD4⁺Foxp3⁺TNFR $2_{CT}^{+}$	1.012	1.000–1.025	0.059^*
CD3⁺PD-L $1_{IM}^{+}$	0.988	0.977–0.999	0.039^**
CD3⁺PD-L $1_{CT}^{+}$	0.996	0.989–1.003	0.223
IDO $_{IM}^{+}$	1.001	0.999–1.004	0.331
IDO $_{CT}^{+}$	1.000	0.999–1.001	0.964
PD- $1_{IM}^{+}$	1.001	0.987–1.014	0.918
PD- $1_{CT}^{+}$	0.996	0.980–1.012	0.616
CD68⁺PD- $1_{IM}^{+}$	1.026	0.992–1.061	0.140^*
CD68⁺PD- $1_{CT}^{+}$	0.852	0.623–1.166	0.318
CD8⁺PD- $1_{IM}^{+}$	1.022	0.998–1.047	0.071^*
CD8⁺PD- $1_{CT}^{+}$	0.925	0.831–1.030	0.157^*
CK $_{IM}^{+}$	1.000	0.998–1.001	0.624
CK $_{CT}^{+}$	0.930	0.998–1.002	0.930
CD $8_{IM}^{+}$	1.002	0.999–1.004	0.267
CD $8_{CT}^{+}$	0.998	0.994–1.002	0.316
CD $68_{IM}^{+}$	1.003	1.000–1.006	0.033^**
CD $68_{CT}^{+}$	0.992	0.980–1.003	0.162^*
CD8⁺IDO $_{IM}^{+}$	1.015	0.988–1.042	0.288
CD8⁺IDO $_{CT}^{+}$	0.995	0.976–1.014	0.604
CD68⁺IDO $_{IM}^{+}$	1.002	0.951–1.055	0.947
CD68⁺IDO $_{CT}^{+}$	0.989	0.944–1.036	0.989

P < 0.2;

^**

P < 0.05.